Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JOENJA vs PONVORY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymphoid tissues, reducing peripheral blood lymphocyte count.
Differentiated thyroid cancer (DTC) refractory to radioactive iodine,Renal cell carcinoma (RCC) in combination with everolimus,Hepatocellular carcinoma (HCC) first-line treatment in combination with pembrolizumab
Relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.
0.5 mg orally once daily, starting with a 7-day titration: Days 1-4: 0.25 mg once daily; Days 5-7: 0.5 mg once daily. Maintenance: 0.5 mg once daily thereafter.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function. This supports once-daily dosing in most indications. Half-life is prolonged in renal impairment, requiring dose adjustment.
Terminal half-life is approximately 11 days (range 8-15 days), supporting once-daily dosing with steady-state reached in about 6-8 weeks.
Primarily metabolized by CYP3A4 and aldehyde oxidase (AO). Minor pathways include CYP3A5 and CYP2C8.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2J2.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose). A small fraction (5-10%) is eliminated via feces via biliary excretion. The remainder is metabolized and excreted as inactive metabolites.
Primarily metabolized via CYP3A4; elimination mainly as metabolites in feces (85-90%) and urine (<1% unchanged).
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations and may be altered in disease states (e.g., hepatic impairment, hypoalbuminemia).
Bound to albumin (~99.7%) and to a lesser extent to α1-acid glycoprotein.
Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests extensive extravascular distribution, with higher concentrations in well-perfused organs (liver, kidneys) and lower in adipose tissue.
Vd ~530 L (approximately 7.6 L/kg for a 70 kg individual); indicates extensive tissue distribution, including into the central nervous system.
Oral bioavailability is approximately 60-70%, with moderate interindividual variability. Food does not significantly affect absorption. No other relevant routes (e.g., topical) are available; bioavailability via IV is 100%.
Oral bioavailability is approximately 93% (range 81-102%), with no significant food effect.
For Cr Cl 30-60 m L/min: 2.5 mg orally once daily; for Cr Cl <30 m L/min (not on dialysis): 1.25 mg orally once daily; for ESRD on dialysis: 2.5 mg orally once daily, dose after dialysis.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For severe renal impairment (e GFR <30 m L/min/1.73 m²), the recommended dose is 0.25 mg orally once daily without titration. Not recommended in patients receiving dialysis.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: The recommended dose is 0.25 mg orally once daily without titration. Child-Pugh Class C: Not recommended.
Safety and efficacy not established in pediatric patients under 18 years.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment; monitor renal function and adjust dose based on Cr Cl.
No specific dose adjustment required for elderly patients (≥65 years) based on age alone. Monitor for adverse effects, as clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
None.
Increased risk of infections, including fatal opportunistic infections; bradyarrhythmia and atrioventricular blocks after initiation; fetal risk; risk of varicella zoster virus reactivation; risk of posterior reversible encephalopathy syndrome (PRES); risk of macular edema.
Hypertension (including hypertensive crisis),Cardiac dysfunction (reduced LVEF),Arterial thromboembolic events,Hepatic impairment (including hepatotoxicity),Renal impairment (including proteinuria),Hemorrhage,Gastrointestinal perforation or fistula,QT prolongation,Reversible posterior leukoencephalopathy syndrome (RPLS),Thyroid dysfunction,Wound healing complications
Monitor for bradyarrhythmia after first dose; risk of infections, including herpes zoster; PML; PRES; macular edema; elevated liver enzymes; respiratory effects; fetal harm; immune system effects; prior use of immunosuppressants; avoid live vaccines.
None known
Within the last 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, NYHA class III/IV heart failure; history of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sinoatrial block unless pacemaker; severe untreated sleep apnea; concurrent use of class Ia or III antiarrhythmics; hypersensitivity to ozanimod or any excipient.
Avoid grapefruit, grapefruit juice, and star fruit as they inhibit CYP3A4 and may increase lapatinib levels. Administer on an empty stomach; food, especially high-fat meals, can increase lapatinib AUC by 2-3 times and Cmax by 3-4 times, increasing toxicity risk.
No significant food interactions. May be taken with or without food. Avoid grapefruit juice only if specifically advised by prescriber due to potential CYP3A4 interaction (though not clinically significant).
First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be avoided in the first trimester unless benefits outweigh risks. Second/third trimester: May cause fetal growth restriction and oligohydramnios; use only if clearly needed.
PONVORY (ponesimod) is contraindicated in pregnancy. Based on animal studies, there is evidence of fetal harm including increased fetal mortality, skeletal abnormalities, and decreased fetal body weight. In humans, the risk is unknown but S1P receptor modulators as a class are associated with teratogenicity. Effective contraception is required during treatment and for 1 week after discontinuation.
Unknown if excreted in human milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 month after last dose.
It is unknown whether ponesimod is excreted in human milk. The M/P ratio is not available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 1 week after the last dose.
Due to increased plasma volume and renal clearance during pregnancy, higher doses may be required. Consider dose titration based on therapeutic drug monitoring and clinical response. No specific dose adjustment is established; individualize therapy.
PONVORY is contraindicated in pregnancy; no dose adjustment is applicable. If pregnancy occurs, discontinue the drug immediately. There are no pharmacokinetic data to suggest dose adjustments needed due to pregnancy-induced changes, as use is contraindicated.
JOENJA (lapatinib) is a dual tyrosine kinase inhibitor of EGFR and HER2. Use with caution in patients with severe hepatic impairment (Child-Pugh C); reduce dose to 750 mg/day. Monitor for QT prolongation, especially in patients with hypokalemia or hypomagnesemia, or those on concurrent QT-prolonging drugs. Diarrhea is common (grades 1-2 in ~50%); premedicate with loperamide and ensure adequate hydration. Hepatotoxicity (ALT >5x ULN) occurs in ~2%; discontinue if severe. Avoid concurrent strong CYP3A4 inducers (e.g., rifampin) as they decrease lapatinib AUC by up to 70%.
PONVORY (ponesimod) is a sphingosine 1-phosphate receptor modulator indicated for relapsing forms of multiple sclerosis (MS). Monitor for bradycardia at treatment initiation; obtain ECG before first dose and observe for 6 hours if resting heart rate <55 bpm, or if on beta-blockers/calcium channel blockers. Assess for infections, macular edema, and liver function before starting. Avoid live attenuated vaccines during and for 4 weeks after treatment. Administer with or without food. Dose titration over 14 days reduces cardiac effects.
Take JOENJA on an empty stomach, at least 1 hour before or 1 hour after a meal; do not take with food as it increases absorption unpredictably.,Do not crush, chew, or split tablets; swallow whole.,If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose.,Avoid grapefruit, grapefruit juice, and star fruit during treatment.,Use effective non-hormonal contraception during treatment and for at least 1 week after the last dose.,Report severe or persistent diarrhea, yellowing of skin or eyes, dark urine, or unusual bruising/bleeding to your healthcare provider.
Take ponestomod exactly as prescribed; do not skip or double doses.,Report any symptoms of bradycardia (dizziness, fainting, slow heartbeat) especially after first dose.,Avoid live vaccines (e.g., MMR, varicella, nasal flu) during treatment and for 4 weeks after stopping.,Contact your doctor immediately if you develop vision changes (blurring, loss of vision) or eye pain.,Notify your physician of any new or worsening infections (fever, cough, painful urination).,Do not stop treatment abruptly; a tapering regimen may be needed to avoid rebound disease activity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JOENJA vs PONVORY, answered by our medical review team.
JOENJA is a Sphingosine 1-Phosphate Receptor Modulator that works by JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.. PONVORY is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymphoid tissues, reducing peripheral blood lymphocyte count.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JOENJA and PONVORY depend on the specific clinical indication. These are both Sphingosine 1-Phosphate Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JOENJA is: JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.. The standard adult dose of PONVORY is: 0.5 mg orally once daily, starting with a 7-day titration: Days 1-4: 0.25 mg once daily; Days 5-7: 0.5 mg once daily. Maintenance: 0.5 mg once daily thereafter.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JOENJA and PONVORY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JOENJA is classified as Category C. First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be . PONVORY is classified as Category C. PONVORY (ponesimod) is contraindicated in pregnancy. Based on animal studies, there is evidence of fetal harm including increased fetal mortality, skeletal abnormalities, and decre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.